Improved properties of TiAlN coatings through the multilayer structure

n/

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

An Experimental Procedure to Estimate Surface Crack Density Using Thermography and Acoustic Emissions

The current study discusses two aspects of an infrared thermography-based local SHM system for monitoring damage evolution during fatigue of composites materials, namely, pre-macrocrack damage (Stage I) followed by subsequent crack growth (Stage II). The crack density is a very well-known damage parameter representing the actual mechanical state of the material in terms of stiffness degradation. In effect, for laminates presenting off-axis laminae, crack density is useful for determining the “characteristic damage state” (CDS) that is related the load carrying capability of the laminate. In present research, a novel procedure is proposed for performing contactless measurements of crack density during static tensile tests by using temperature signal. The results have been critically compared with the strain waves signal acquired by acoustic emission sensors during the same tests. The proposed technique and procedure lead to estimate the crack density in those applications where it is difficult to detect transverse crack using a direct measurement from common experimental techniques

Thermographic signal analysis of friction stir welded AA 5754 H111 joints

Aluminium alloys present some criticalities in terms of fatigue life characterisation due to the absence of a point representing the 'fatigue limit', the topic becomes complicated when the material is welded. In this case, the fatigue characterisation lies on design specifications which have to clearly explain the guidelines for the performing the tests and for evaluating the failures, in order to design tailored welded joints. However, the fatigue of welded joints is a difficult subject since the welding process makes the material different, introducing residual tensions, defect, etc. Also, the standard test methods provide only the estimation of the strength at fixed loading cycles but no information on the damage processes occurring in the material.Prompted by these issues researchers deal with the study of other approaches to achieve not only information on fatigue resistance but also damage information. In particular, the thermography can be used for thermal signal analysis of dissipative heat sources involved in fatigue of material undergoing cyclic test.In this paper, this approach is adopted to study the fatigue behavior of friction stir welded joints of AA5754-H111 during specific loading conditions. The component of the temperature related to intrinsic dissipations is assessed and the fatigue strength is evaluated together with a graphical study of the location of damaged areas

Lock-in thermography on moving samples: amazing mismatch between amplitude and phase

International audienc